The director buys post-strong earnings are a modest incremental positive, but the dollar amount is too small to drive institutional sentiment. Monitor for any c-suite open-market purchases to confirm director conviction. The stock remains 39% analyst-bullish with consensus hold, no immediate catalyst beyond earnings guidance.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $26.20entry
- T+1 · 3mo ago +2.14%α +1.53% · $26.76
- T+5 · 3mo ago +2.29%α +1.08% · $26.80
- T+20 · 2mo ago +9.95%α +9.35% · $28.81
- T+60 · 17d ago +16.49%α +18.16% · $30.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Pfizer directors (Blaylock and Buckley) made open-market purchases totaling ~$1.96M on the same day the company's SVP & Controller sold $83K. The director buys follow Pfizer's Q2 2026 earnings beat (reported Aug 4) where adjusted EPS of $0.77 beat consensus by 12.9% and revenue of $15.0B beat by 4.5%, alongside raised full-year guidance. The insider purchases suggest directors see value at the current ~$25.50/share level post-earnings, though the $1.96M total is tiny (0.0013% of Pfizer's $149B market cap) and the controller's small sale appears liquidity-driven.
Key Financial Metrics
Key Facts
- Two directors purchased 76.9K shares total for ~$1.96M on Aug 5, one day after Pfizer reported Q2 2026 earnings beat
- SVP & Controller Damico sold 3.3K shares for $83K on the same day (liquidity-sized, 0.00006% of market cap)
- Total insider buying of $1.96M is 0.0013% of Pfizer's $149.3B market cap, economically trivial
- Q2 2026 adjusted EPS of $0.77 beat consensus of $0.68 by 12.9%; revenue $15.0B beat $14.4B by 4.5%
- Full-year 2026 revenue guidance raised by $500M midpoint to $60.5-$62.5B; adj EPS guidance $2.80-$3.00 reaffirmed
Financial Impact
$1.96M in director open-market purchases, 0.0013% of $149.3B market cap
Risk Factors
- Insider buying at 0.0013% of market cap is too small to move the stock
- GAAP net loss of $0.04 per share in Q2 due to $4.3B non-cash impairments tempers headline bullishness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PFE-1786083420400 |
Track record
21 reports on PFE
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202617d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Viewing Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers